Similarly, both a larger sample size and longer follow-up would have resulted in a higher number of cardiovascular events, perhaps allowing differences to be observed between persistent and non-persistent subjects
Eli Lilly on Thursday estimated that it will produce at least 1.6 times the amount of incretin doses in the first half of 2025 compared with the first half of 2024
Of note, semaglutide is not recommended in patients with severe gastrointestinal disease, including severe gastroparesis, as stated in the SmPC
Theyre likely to be taking these drugs for shorter durations, so any consumer-facing company thats adjusting product and marketing strategies in response to the rise in usage rates were seeing for these drugs should also be taking into account that a larger underlying user base means that we'll be seeing a growing number of consumers who are also stopping and ceasing these drugs over time as well. How To Respond In addressing how retailers and food and beverage companies should respond, Circana said that while some consumers will resume their pre-GLP-1 purchase habits when they cease treatment, for many others, varying forms of the medication, supplements and CPG food and beverage will play critical roles in how individuals manage their conditions. Some areas of opportunity include: Product innovation: Develop and promote products that align with the dietary needs of GLP-1 users, Circana said
En cambio, la nueva sustancia activa el metabolismo del msculo esqueltico
.png)
